1-20 of 43
glucagon-like peptide-1 agonists
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Improving Prescribing Rates of Glucagon-Like Peptide 1 Receptor Agonists in Youth With Type 2 Diabetes

Available to Purchase
Alyssa Huang, Alissa Roberts, Yasi Mohsenian, Grace Kim
Journal: Clinical Diabetes
Clin Diabetes 2025;43(3):429–434
https://doi.org/10.2337/cd24-0070
Published: 13 February 2025
View article titled, Improving Prescribing Rates of Glucagon-Like Peptide 1 Receptor Agonists in Youth With Type 2 Diabetes
Open the PDF for Improving Prescribing Rates of Glucagon-Like Peptide 1 Receptor Agonists in Youth With Type 2 Diabetes in another window
Journal Articles

Insulin Titration Recommendations When Using Glucagon-Like Peptide 1 Receptor Agonist Therapy in Adults With Type 1 Diabetes

Available to Purchase
Zeb I. Saeed, Halis K. Akturk, Grazia Aleppo, Davida Kruger, Carol J. Levy, Julia K. Mader, Jennifer L. Sherr, Viral N. Shah
Journal: Clinical Diabetes
Clin Diabetes 2025;43(1):131–138
https://doi.org/10.2337/cd24-0067
Published: 20 September 2024
View article titled, Insulin Titration Recommendations When Using Glucagon-Like Peptide 1 Receptor Agonist Therapy in Adults With Type 1 Diabetes
Open the PDF for Insulin Titration Recommendations When Using Glucagon-Like Peptide 1 Receptor Agonist Therapy in Adults With Type 1 Diabetes in another window
Journal Articles

Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk

Available to Purchase
Rozalina G. McCoy, Kavya Sindhu Swarna, Joshua J. Neumiller, Eric C. Polley, Yihong Deng, Mindy M. Mickelson, Jeph Herrin
Journal: Clinical Diabetes
Clin Diabetes 2025;43(1):59–70
https://doi.org/10.2337/cd24-0007
Published: 13 September 2024
View article titled, Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk
Open the PDF for Risk of Severe Hypoglycemia After Initiation of Noninsulin Glucose-Lowering Therapies in Adults With Type 2 Diabetes at Moderate Cardiovascular Disease Risk in another window
Journal Articles

A National Physician Survey Examining Switching From Sulfonylureas or Insulin to Newer Diabetes Medications

Available to Purchase
Scott J. Pilla, Isabelle J. Wang, Olive Tang, Nancy L. Schoenborn, Cynthia M. Boyd, Michael P. Bancks, Nestoras N. Mathioudakis, Nisa M. Maruthur
Journal: Clinical Diabetes
Clin Diabetes 2025;43(1):33–42
https://doi.org/10.2337/cd24-0043
Published: 05 September 2024
View article titled, A National Physician Survey Examining Switching From Sulfonylureas or Insulin to Newer Diabetes Medications
Open the PDF for A National Physician Survey Examining Switching From Sulfonylureas or Insulin to Newer Diabetes Medications in another window
Journal Articles

A1C: Episode 3

Free
Nay Linn Aung
Journal: Clinical Diabetes
Clin Diabetes 2024;42(3):448–451
https://doi.org/10.2337/cd24-0038
Published: 02 May 2024
View article titled, A1C: Episode 3
Open the PDF for A1C: Episode 3 in another window
Journal Articles

Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes

Free
Roy W. Beck, Carol J. Levy, Yogish C. Kudva, Keta Pandit, Thomas Blevins, Dan Raghinaru, Jordan E. Pinsker
Journal: Clinical Diabetes
Clin Diabetes 2024;42(4):547–549
https://doi.org/10.2337/cd23-0107
Published: 17 April 2024
View article titled, Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes
Open the PDF for Beneficial Effects of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist Use With Control-IQ Technology in Type 2 Diabetes in another window
Journal Articles

Timely News and Notes for Primary Care Providers from the American Diabetes Association

Free
Max Bingham, PhD
Journal: Clinical Diabetes
Clin Diabetes 2024;42(1):5–9
https://doi.org/10.2337/cd24-dp01
Published: 15 January 2024
View article titled, Timely News and Notes for Primary Care Providers from the American Diabetes Association
Open the PDF for Timely News and Notes for Primary Care Providers from the American Diabetes Association in another window
Journal Articles

Accidental Once-Daily Use of Dulaglutide: A Case Report

Free
Hannah E. Moore, Viva Zaya, Carly V. Burns, Helen D. Berlie
Journal: Clinical Diabetes
Clin Diabetes 2024;42(3):454–457
https://doi.org/10.2337/cd23-0035
Published: 12 January 2024
View article titled, Accidental Once-Daily Use of Dulaglutide: A Case Report
Open the PDF for Accidental Once-Daily Use of Dulaglutide: A Case Report in another window
Journal Articles

Use of Continuous Glucose Monitoring and Glucagon-Like Peptide 1 Receptor Agonist Therapy to Achieve Individualized Treatment Goals in Insulin-Treated People With Type 2 Diabetes: A Case Series and Expert Opinion

Free
Nicole M. Ehrhardt, Vanita R. Aroda, Rodolfo J. Galindo, Anne L. Peters, Jay H. Shubrook
Journal: Clinical Diabetes
Clin Diabetes 2024;42(2):341–350
https://doi.org/10.2337/cd23-0047
Published: 05 December 2023
View article titled, Use of Continuous Glucose Monitoring and Glucagon-Like Peptide 1 Receptor Agonist Therapy to Achieve Individualized Treatment Goals in Insulin-Treated People With Type 2 Diabetes: A Case Series and Expert Opinion
Open the PDF for Use of Continuous Glucose Monitoring and Glucagon-Like Peptide 1 Receptor Agonist Therapy to Achieve Individualized Treatment Goals in Insulin-Treated People With Type 2 Diabetes: A Case Series and Expert Opinion in another window
Journal Articles

Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study

Free
Aseel Yaseen, Sharon W. Lahiri
Journal: Clinical Diabetes
Clin Diabetes 2023;41(4):490–501
https://doi.org/10.2337/cd22-0100
Published: 14 April 2023
View article titled, Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study
Open the PDF for Health Care Provider Prescribing Habits and Barriers to Use of New Type 2 Diabetes Medications: A Single-System Survey Study in another window
Journal Articles

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages

Free
Heather P. Whitley, Jennifer M. Trujillo, Joshua J. Neumiller
Journal: Clinical Diabetes
Clin Diabetes 2023;41(3):467–473
https://doi.org/10.2337/cd23-0023
Published: 07 April 2023
View article titled, Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
Open the PDF for Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages in another window
Journal Articles

Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin

Free
Alexis V. Fanshier, Brianne K. Crews, Madison C. Garrett, Jeremy L. Johnson
Journal: Clinical Diabetes
Clin Diabetes 2023;41(3):367–377
https://doi.org/10.2337/cd22-0060
Published: 02 March 2023
View article titled, Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin
Open the PDF for Tirzepatide: A Novel Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide 1 Receptor Agonist for the Treatment of Type 2 Diabetes: The First Twincretin in another window
Journal Articles

Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?

Free
Aaron King, Eden M. Miller
Journal: Clinical Diabetes
Clin Diabetes 2023;41(2):226–238
https://doi.org/10.2337/cd22-0027
Published: 03 November 2022
View article titled, Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low?
Open the PDF for Glucagon-Like Peptide 1 Receptor Agonists Have the Potential to Revolutionize the Attainment of Target A1C Levels in Type 2 Diabetes—So Why Is Their Uptake So Low? in another window
Journal Articles

A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist

Free
Muralikrishna Gangadharan Komala, Jasveen Renthawa
Journal: Clinical Diabetes
Clin Diabetes 2022;40(4):508–510
https://doi.org/10.2337/cd21-0142
Published: 14 October 2022
View article titled, A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist
Open the PDF for A Case of Dulaglutide-Induced Acute Interstitial Nephritis After Many Years of Treatment With an Alternate GLP-1 Receptor Agonist in another window
Journal Articles

Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy

Free
Kaylan N. Davis, Abigail E. Hines, Margaret C. Schaefer, Kristina W. Naseman
Journal: Clinical Diabetes
Clin Diabetes 2022;40(3):305–311
https://doi.org/10.2337/cd21-0090
Published: 01 July 2022
View article titled, Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy
Open the PDF for Protecting the Kidneys: Update on Therapies to Treat Diabetic Nephropathy in another window
Journal Articles

Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary

Free
John Anderson, James R. Gavin, III, Davida F. Kruger, Eden Miller
Journal: Clinical Diabetes
Clin Diabetes 2022;40(3):265–269
https://doi.org/10.2337/cd22-0020
Published: 01 July 2022
View article titled, Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary
Open the PDF for Optimizing the Use of Glucagon-Like Peptide 1 Receptor Agonists in Type 2 Diabetes: Executive Summary in another window
Journal Articles

Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance

Free
Jaime P. Almandoz, Ildiko Lingvay, Javier Morales, Carlos Campos
Journal: Clinical Diabetes
Clin Diabetes 2020;38(4):390–402
https://doi.org/10.2337/cd19-0100
Published: 01 October 2020
View article titled, Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance
Open the PDF for Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance in another window
Journal Articles

How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?

Free
Joseph Tibaldi, Max E. Mercado, Jodi Strong
Journal: Clinical Diabetes
Clin Diabetes 2020;38(4):339–347
https://doi.org/10.2337/cd20-0014
Published: 01 October 2020
View article titled, How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice?
Open the PDF for How Effective Is the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) in Different Patient Populations, and When Should It Be Used in Clinical Practice? in another window
Journal Articles

Lessons From a Diabetes Clinic: Achieving Glycemic Goals and Clinical Use of Antidiabetic Agents in Patients With Type 2 Diabetes

Free
Iakovos Avramidis, Athanasia Apsemidou, Antigoni Z. Lalia, Nikolaos Petridis, Euangelos Tourtouras, Georgios Kalopitas, Georgios Pilianidis
Journal: Clinical Diabetes
Clin Diabetes 2020;38(3):248–255
https://doi.org/10.2337/cd19-0090
Published: 01 July 2020
View article titled, Lessons From a Diabetes Clinic: Achieving Glycemic Goals and Clinical Use of Antidiabetic Agents in Patients With Type 2 Diabetes
Open the PDF for Lessons From a Diabetes Clinic: Achieving Glycemic Goals and Clinical Use of Antidiabetic Agents in Patients With Type 2 Diabetes in another window
Journal Articles

Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?

Open Access
Robert H. Eckel, Azeez Farooki, Robert R. Henry, Gary G. Koch, Lawrence A. Leiter
Journal: Clinical Diabetes
Clin Diabetes 2019;37(4):316–337
https://doi.org/10.2337/cd19-0001
Published: 01 October 2019
View article titled, Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?
Open the PDF for Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice? in another window